|
gptkbp:instanceOf
|
gptkb:liposomal_amphotericin_B
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:amphotericin_B
|
|
gptkbp:advantage
|
reduced nephrotoxicity compared to conventional amphotericin B
|
|
gptkbp:alternativeTo
|
gptkb:conventional_amphotericin_B
|
|
gptkbp:approvalYear
|
1991
1997
|
|
gptkbp:approvedBy
|
gptkb:Europe
|
|
gptkbp:ATCCode
|
gptkb:J02AA01
|
|
gptkbp:brand
|
gptkb:AmBisome
|
|
gptkbp:CASNumber
|
1397-89-3 (amphotericin B)
|
|
gptkbp:chemicalFormula
|
C47H73NO17 (amphotericin B)
|
|
gptkbp:color
|
yellow
|
|
gptkbp:contraindication
|
hypersensitivity to amphotericin B
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:India
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:form
|
liposomal
powder for solution for infusion
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:halfLife
|
7–15 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AmBisome
|
|
gptkbp:indication
|
gptkb:mucormycosis
gptkb:visceral_leishmaniasis
candidiasis
aspergillosis
cryptococcal meningitis
systemic fungal infections
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
binds to ergosterol in fungal cell membrane
forms pores in fungal cell membrane
|
|
gptkbp:patent
|
gptkb:Gilead_Sciences
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
>90%
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
fever
nausea
vomiting
chills
hypokalemia
nephrotoxicity
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:usedIn
|
hospitals
treatment of immunocompromised patients
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:amphotericin_B
|
|
gptkbp:bfsLayer
|
6
|